Time-dependent clearance of mycophenolic acid in renal transplant recipients

被引:72
作者
van Hest, Reinier M.
van Gelder, Teun
Bouw, Rene
Goggin, Timothy
Gordon, Robert
Mamelok, Richard D.
Mathot, Ron A.
机构
[1] Erasmus MC, Dept Hosp Pharm, Clin Pharmacol Unit, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[3] Roche Prod Ltd, Welwyn Garden City, Herts, England
[4] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[5] Roche Labs Inc, Nutley, NJ USA
[6] Mamelok Consulting, Palo Alto, CA USA
关键词
mycophenolic acid; pharmacokinetics; renal transplantation; time-dependent clearance;
D O I
10.1111/j.1365-2125.2006.02841.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Pharmacokinetic studies of the immunosuppressive compound mycophenolic acid (MPA) have shown a structural decrease in clearance (CL) over time after renal transplantation. The aim of this study was to characterize the time-dependent CL of MPA by means of a population pharmacokinetic meta-analysis, and to test whether it can be described by covariate effects. Methods One thousand eight hundred and ninety-four MPA concentration-time profiles from 468 renal transplant patients (range 1-9 profiles per patient) were analyzed retrospectively by nonlinear mixed effect modelling. Sampling occasions ranged from day 1-10 years after transplantation. Results The pharmacokinetics of MPA were described by a two-compartment model with time-lagged first order absorption, and a first-order term for time-dependent CL. The model predicted the mean CL to decrease from 35 l h(-1) (CV = 44%) in the first week after transplantation to 17 l h(-1) (CV = 38%) after 6 months. In a covariate model without a term for time-dependent CL, changes during the first 6 months after transplantation in creatinine clearance from 19 to 71 ml min(-1), in albumin concentration from 35 to 40 g l(-1), in haemoglobin from 9.7 to 12 g dl(-1) and in cyclosporin predose concentration from 225 to 100 ng ml(-1) corresponded with a decrease of CL from 32 to 19 l h(-1). Creatinine clearance, albumin concentration, haemoglobin and cyclosporin predose concentration explained, respectively, 19%, 12%, 4% and 3% of the within-patient variability in MPA CL. Conclusions By monitoring creatinine clearance, albumin concentration, haemoglobin and cyclosporin predose concentration, changes in MPA exposure over time can be predicted. Such information can be used to optimize therapy with mycophenolate mofetil.
引用
收藏
页码:741 / 752
页数:12
相关论文
共 42 条
  • [1] [Anonymous], TRANSPLANTATION S
  • [2] Beal SL., 1998, NONMEM Users Guides
  • [3] Higher exposure to mycophcnolic acid with sirohmus than with cyclosporine cotreatment
    Büchler, M
    Lebranchu, Y
    Bénéton, M
    Le Meur, Y
    Heng, AE
    Westeel, PF
    le Guellec, C
    Libert, F
    Hary, L
    Marquet, P
    Paintaud, G
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (01) : 34 - 42
  • [4] Clinical pharmacokinetics of mycophenolate mofetil
    Bullingham, RES
    Nicholls, AJ
    Kanmm, BR
    [J]. CLINICAL PHARMACOKINETICS, 1998, 34 (06) : 429 - 455
  • [5] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [6] Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling
    Cremers, S
    Schoemaker, R
    Scholten, E
    den Hartigh, J
    König-Quartel, J
    van Kan, E
    Paul, L
    de Fijter, J
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (03) : 249 - 256
  • [7] Danovitch G, 1997, TRANSPL P, V29, P348
  • [8] Population pharmacokinetic modeling: The importance of informative graphics
    Ette, EI
    Ludden, TM
    [J]. PHARMACEUTICAL RESEARCH, 1995, 12 (12) : 1845 - 1855
  • [9] Stability and performance of a population pharmacokinetic model
    Ette, EI
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (06) : 486 - 495
  • [10] The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation
    Hale, MD
    Nicholls, AJ
    Bullingham, RES
    Hené, R
    Hoitsma, A
    Squifflet, JP
    Weimar, W
    Vanrenterghem, Y
    Van de Woude, FJ
    Verpooten, GA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (06) : 672 - 683